TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›AZN

AZN

ASTRAZENECA PLC

Next earnings Jul 27, 2026 · consensus $2.58 EPS, $15.9B rev

Sell
$195.15
▲ +2.20%
$195.15▲ +42.14%
over 1Y
L $135.07H $208.45
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.2%
1W+5.1%
1M+10.0%
3M-4.1%
YTD+7.7%
1Y+42.1%
OverviewValuationQualityFilings
Rating
Sell
Quality
B+
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 35 analysts
Buy

Mixed signals in the latest filings.

ASTRAZENECA PLC shows limited reported revenue.

On these fundamentals, AZN screens as SELL on the SEC figures.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:20 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Key statistics

Valuation

Enterprise value$303B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-07-012026-07-01open ↗6-KPeriod ending 2026-07-012026-07-01open ↗11-KPeriod ending 2025-12-312026-06-29open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-292026-06-29open ↗4Period ending 2026-06-082026-06-16open ↗6-KPeriod ending 2026-06-152026-06-15open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-06-012026-06-01open ↗6-KPeriod ending 2026-05-292026-05-29open ↗25-NSEFiling2026-05-28open ↗6-KPeriod ending 2026-05-272026-05-27open ↗

Quality score

B+
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumB+
135.0752-week208.45
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is ASTRAZENECA PLC (AZN) a buy?
AZN currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is ASTRAZENECA PLC's quality score?
AZN scores 79.51214791472772/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000901832, latest 6-K filed 2026-07-01) · EODHD · as of 7/4/2026, 2:20:13 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-06-08
Sharma Mani
See Remarks
Award1.00 @ $179.75$179.75
2026-05-20
Sharma Mani
See Remarks
Sell11.9K @ $185.78$2.21M
2026-05-06
Sharma Mani
See Remarks
Award1.00 @ $186.28$186.28
2026-04-07
Sharma Mani
See Remarks
Award1.00 @ $196.03$196.03
2021-03-15
ASTRAZENECA PLC
10% owner
Disposed (U)14.7M @ $53.00$776M
2019-12-19
ASTRAZENECA PLC
10% owner
Buy12.9M
2019-10-07
ASTRAZENECA PLC
10% owner
Acquired (C)14.2M
2019-10-07
ASTRAZENECA PLC
10% owner
Buy425K @ $19.00$8.07M

Dividends

Semi-annual
Yield (TTM)
1.6%
Annual / share
$3.20
Last ex-date
2026-02-20
Last amount
$2.17
ex 2026-02-20paid 2026-03-23$2.17
ex 2025-08-08paid 2025-09-08$1.03
ex 2025-02-21paid 2025-03-24$2.10
ex 2024-08-09paid 2024-09-09$1.00
ex 2024-02-22paid 2024-03-25$1.97
ex 2023-08-10paid 2023-09-11$0.93

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Congressional trades

all activity →

2 buys · 2 members · last 180d

+$16.0K net boughtlast trade 199d ago
$16.0K bought$0.00 sold
2026-01-13Julia LetlowBuy$1.00K–$15.0KPTR ↗
2026-01-12Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-12-15Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-18Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-10-10Valerie HoyleSell$1.00K–$15.0KPTR ↗
2025-09-12Valerie HoyleBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?Bullish
nasdaq.com· 2026-07-03
[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Bullish
finance.yahoo.com· 2026-07-03
UK Cardiovascular Clinical Trials Market Projected to Reach USD 892.2 Million by 2033Bullish
globenewswire.com· 2026-07-03
AstraZeneca (LSE:AZN) Wins Two EU Cancer Approvals And Starts Abbisko Lung TrialBullish
finance.yahoo.com· 2026-07-02
FTSE 100 rises as US jobs data eases Fed rate hike fearsBullish
uk.finance.yahoo.com· 2026-07-02
European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares RallyBullish
finance.yahoo.com· 2026-07-02

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score80 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 50d
Bearish
-0.09
vs typical · 201 articles
↓ cooling

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.